Recordati SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0003828271
EUR
50.80
-5.07 (-9.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

434.75 k

Shareholding (Mar 2026)

FII

0.01%

Held by 3 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Operating profit has grown by an annual rate 2.20% of over the last 5 years

 
2

With ROE of 0.00%, it has a Very Expensive valuation with a 0.00 Price to Book Value

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 10,624 Million ()

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

32.97%

stock-summary
Debt Equity

0.86

stock-summary
Return on Equity

24.65%

stock-summary
Price to Book

5.16

Revenue and Profits:
Net Sales:
713 Million
(Quarterly Results - Mar 2026)
Net Profit:
153 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.96%
0%
-8.96%
6 Months
23.84%
0%
23.84%
1 Year
46.4%
0%
46.4%
2 Years
35.94%
0%
35.94%
3 Years
20.95%
0%
20.95%
4 Years
60.25%
0%
60.25%
5 Years
97.67%
0%
97.67%

Recordati SpA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
12.56%
EBIT Growth (5y)
2.20%
EBIT to Interest (avg)
16.62
Debt to EBITDA (avg)
1.95
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.58
Tax Ratio
24.13%
Dividend Payout Ratio
62.07%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
19.37%
ROE (avg)
25.39%

Valuation key factors

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
NA
EV to EBIT
18.73
EV to EBITDA
14.53
EV to Capital Employed
NA
EV to Sales
3.78
PEG Ratio
2.65
Dividend Yield
22.89%
ROCE (Latest)
NA
ROE (Latest)
NA

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 7.73% vs 4.73% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 30.52% vs 6.44% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "713.40",
          "val2": "662.20",
          "chgp": "7.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "284.20",
          "val2": "245.00",
          "chgp": "16.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "24.00",
          "val2": "24.90",
          "chgp": "-3.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-15.00",
          "chgp": "90.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "153.10",
          "val2": "117.30",
          "chgp": "30.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "324.80%",
          "val2": "289.00%",
          "chgp": "3.58%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.82% vs 12.45% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.51% vs 7.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,618.40",
          "val2": "2,341.60",
          "chgp": "11.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "926.20",
          "val2": "826.90",
          "chgp": "12.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "98.90",
          "val2": "81.20",
          "chgp": "21.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-47.00",
          "val2": "-22.40",
          "chgp": "-109.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "443.60",
          "val2": "416.50",
          "chgp": "6.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "274.90%",
          "val2": "281.80%",
          "chgp": "-0.69%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
713.40
662.20
7.73%
Operating Profit (PBDIT) excl Other Income
284.20
245.00
16.00%
Interest
24.00
24.90
-3.61%
Exceptional Items
-1.50
-15.00
90.00%
Consolidate Net Profit
153.10
117.30
30.52%
Operating Profit Margin (Excl OI)
324.80%
289.00%
3.58%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 7.73% vs 4.73% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 30.52% vs 6.44% in Dec 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,618.40
2,341.60
11.82%
Operating Profit (PBDIT) excl Other Income
926.20
826.90
12.01%
Interest
98.90
81.20
21.80%
Exceptional Items
-47.00
-22.40
-109.82%
Consolidate Net Profit
443.60
416.50
6.51%
Operating Profit Margin (Excl OI)
274.90%
281.80%
-0.69%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 11.82% vs 12.45% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 6.51% vs 7.01% in Dec 2024

stock-summaryCompany CV
About Recordati SpA stock-summary
stock-summary
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates stock-summary
Company Details
Via M. Civitali, 1 , MILANO None : 20148
stock-summary
Tel: 39 02 48787139 02 48787393
stock-summary
Registrar Details